LRRK2 and Parkinson disease: Our first experiment was performed to compare results with the previous report by Fraser et al17, i.e. using similar sample groups (male individuals, including healthy controls, idiopathic PD patients, healthy LRRK2 G2019S carriers and LRRK2 G2019S carriers with PD) and with similar modes of sample processing and signal detections/quantification.